Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)-Reference-Cited by-同舟云学术

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

Published:2022-07-15 Issue:3 Volume:76 Page:e526-e529
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Boucau Julie¹,Uddin Rockib²,Marino Caitlin¹,Regan James³,Flynn James P³,Choudhary Manish C³⁴,Chen Geoffrey²,Stuckwisch Ashley M²,Mathews Josh²,Liew May Y²,Singh Arshdeep²,Reynolds Zahra²,Iyer Surabhi L²,Chamberlin Grace C²,Vyas Tammy D²,Vyas Jatin M²⁴,Turbett Sarah E²,Li Jonathan Z³⁴,Lemieux Jacob E²⁴⁵,Barczak Amy K¹²⁴^ORCID,Siedner Mark J²⁴

Affiliation:

1. Ragon Institute of Massachusetts General Hospital (MGH) , Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts , USA

2. Massachusetts General Hospital , Boston, Massachusetts , USA

3. Brigham and Women’s Hospital , Boston, Massachusetts , USA

4. Harvard Medical School , Boston, Massachusetts , USA

5. Broad Institute , Cambridge, Massachusetts , USA

Abstract

Abstract We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

Funder

Massachusetts Consortium for Pathogen Readiness

Massachusetts General Hospital Department of Medicine

Harvard

CFAR)

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac512/44933481/ciac512.pdf

Reference10 articles.